<DOC>
	<DOC>NCT00997152</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.</brief_summary>
	<brief_title>Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Have type 2 diabetes; 2. Body mass index (BMI) of â‰¤ 45.0 kg/m2; 3. Are either untreated with respect to hypoglycemic agents OR are currently being treated with a stable dose of metformin alone. 1. Females who are pregnant or breastfeeding; 2. Known medical history or presence of type 1 diabetes or pancreatitis, acute metabolic diabetic complications, presence of unstable or rapidly progressing retinopathy, nephropathy or neuropathy; 3. Acute coronary syndrome or uncontrolled hypertension; 4. Does not meet all diet or previous/concomitant medication restrictions criteria, as described in the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Diabetes</keyword>
</DOC>